Research Summary

My non-clinical work focuses on developing and evaluating risk assessment tools for breast cancer and using those tools to efficiently use screening technologies and preventive therapies to decrease the burden of breast cancer in our community.

I also perform technology assessments and support cost-effectiveness modeling and budget impact analyses for new medications, medical devices, and health system interventions for the Institute for Clinical and Economic Review.

Education

Dartmouth College, Hanover, NH, BA, 06/1983, Math; Philosophy
San Francisco State University, 05/1989, Pre-medical classed
University of California, San Francisco, MD, 06/1994, Medicine
University of California, San Francisco, 06/1997, Internal Medicine
University of California, San Francisco, Postdoctoral, 06/1999, Research/Epidmiology

Honors & Awards

  • 2013
    UCSF Research Mentoring Award
  • 2009
    Society of General Internal Medicine- CA Region- Outstanding Clinician Investigator Award
  • 2003
    Robert Crede Award for Clinical Research, UCSF Division of General Internal Medicine
  • 2002-2004
    Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Faculty Scholar
  • 1994
    Alpha Omega Alpha, UCSF
  • 1990-1994
    Regents Scholarship, UCSF
  • 1983
    Summa Cum Laude, Dartmouth College
  • 1982
    Phi Beta Kappa, Dartmouth College
  • 1979-1983
    Rufous Choate Scholar, Dartmouth College
  • 1979-1983
    IBM Thomas J. Watson Scholar

Selected Publications

  1. Tice JA, Kuntz KM, Wherry K, Seidner M, Rind DM, Pearson SD The effectiveness and value of novel treatments for cystic fibrosis.  View on PubMed
  2. Tice JA, Halalau A, Burke H Vitamin D Does Not Prevent Cancer or Cardiovascular Disease: The VITAL Trial : Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE  View on PubMed
  3. Shieh Y, Tice JA Medications for Primary Prevention of Breast Cancer.  View on PubMed
  4. Tice JA, Guzauskas GF, Hansen RN, Herron-Smith S, Segel C, Walsh JME, Pearson SD The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy.  View on PubMed
  5. Trabert B, Bauer DC, Buist DSM, Cauley JA, Falk RT, Geczik AM, Gierach GL, Hada M, Hue TF, Lacey JV, LaCroix AZ, Tice JA, Xu X, Dallal CM, Brinton LA Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women.  View on PubMed
  6. Tice JA, Campbell JD, Synnott PG, Walsh JME, Kumar VM, Whittington M, Adair E, Rind D, Pearson SD The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma.  View on PubMed
  7. Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E A response to "Personalised medicine and population health: breast and ovarian cancer".  View on PubMed
  8. Tice JA, Bissell MCS, Miglioretti DL, Gard CC, Rauscher GH, Dabbous FM, Kerlikowske K Validation of the breast cancer surveillance consortium model of breast cancer risk.  View on PubMed
  9. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.  View on PubMed
  10. Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, Chapman RH, Kumar V, Carlson JJ Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.  View on PubMed
  11. Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.  View on PubMed
  12. Ozanne E, Karliner LS, Tice JA, Haas JS, Livaudais-Toman J, Pasick RJ, Kaplan CP An Intervention Tool to Increase Patient-Physician Discussion of Lifestyle Risk Factors for Breast Cancer.  View on PubMed
  13. Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort.  View on PubMed
  14. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.  View on PubMed
  15. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.  View on PubMed
  16. Tice JA, Kerlikowske K Supplemental Breast Cancer Screening: A Density Conundrum.  View on PubMed
  17. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.  View on PubMed
  18. Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.  View on PubMed
  19. Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.  View on PubMed
  20. Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.  View on PubMed

Go to UCSF Profiles, powered by CTSI